Please login to the form below

Not currently logged in

Imbruvica shines in combination trial

Showed significant increase in progression-free survival


A phase III trial of Johnson & Johnson (J&J) and Pharmacyclics' Imbruvica in combination with two other drugs has been halted early after the regimen showed a significant benefit.

Adding Imbruvica (ibrutinib) to therapy with Biogen Idec's Rituxan (rituximab) and bendamustine resulted in a significant increase in progression-free survival (PFS), according to the results of the HELIOS trial, which enrolled patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

As a result, the trial's independent data monitoring committee has recommended that the study be un-blinded and patients receiving placebo offered the option to receive Imbruvica.

The data from the trial will form the basis of a regulatory filing to extend the indications of Imbruvica to include combination therapy, according to Pharmacyclics, which agreed to be taken over by AbbVie in a deal valued at around $21bn.

Imbruvica is one of J&J's top growth products in oncology and pulled in $200m in 2014, its first full year on the market, and has been tipped to become a blockbuster with sales of more than $1bn this year and almost $6bn at peak.

The drug is a Bruton's tyrosine kinase (BTK) inhibitor - licensed by J&J from Pharmacyclics in 2011 in a deal valued at up to $975m - and recently became the first drug approved by the FDA to treat Waldenström's macroglobulinaemia (WM), having already been cleared for CLL and mantle cell lymphoma (MCL).

The HELIOS study enrolled 578 previously-treated CLL and SLL patients – excluding those with a particular cancer mutation called a 17p deletion - who received rituximab and bendamustine for up to six cycles along with either placebo or ibrutinib. Top line data from the trial will be presented at the American Society of Clinical Oncology (ASCO) meeting later this year.

An earlier trial of the drug as a single-agent therapy in CLL indicated it was more effective than GlaxoSmithKline (GSK) and Genmab's Arzerra (ofatumumab).

Article by
Phil Taylor

17th March 2015

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...